Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orly Vardeny

Showing results (1-10 of 168) with videos related to

Pageof 17
Sort By:
The American Journal of Medicine|September 9, 2019
The Sweet Spot: Heart Failure Prevention with SGLT2 InhibitorsOrly Vardeny
Pharmacotherapy|April 6, 2023
Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fractionOrly Vardeny, Hailee Houle
Current Heart Failure Reports|October 16, 2015
The Role of Neprilysin Inhibitors in Cardiovascular DiseaseJared Mills, Orly Vardeny
JACC. Heart Failure|February 2, 2019
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for CardiologistsOrly Vardeny, Muthiah Vaduganathan
Journal of Herbal Pharmacotherapy|March 8, 2006
The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS)Orly Vardeny, Mark B Bromberg
Cardiology Clinics|October 22, 2008
Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular riskOrly Vardeny, Scott D Solomon
Pharmacogenomics|November 5, 2016
Pharmacogenomics of heart failure: a systematic reviewFannie Mottet, Orly Vardeny, Simon de Denus
Heart Failure Reviews|May 26, 2026
Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art reviewHarriette G C Van Spall, Orly Vardeny
JACC. Heart Failure|October 13, 2014
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failureOrly Vardeny, Ryan Miller, Scott D Solomon
Heart Rhythm|July 2, 2020
Effects of hydroxychloroquine treatment on QT intervalMatthew Hooks, Bradley Bart, Orly Vardeny, et al.
Pageof 17

Showing results (1-10 of 168) with videos related to

Sort By:
Pageof 17
The American Journal of Medicine|September 9, 2019
The Sweet Spot: Heart Failure Prevention with SGLT2 InhibitorsOrly Vardeny
Pharmacotherapy|April 6, 2023
Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fractionOrly Vardeny, Hailee Houle
Current Heart Failure Reports|October 16, 2015
The Role of Neprilysin Inhibitors in Cardiovascular DiseaseJared Mills, Orly Vardeny
JACC. Heart Failure|February 2, 2019
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for CardiologistsOrly Vardeny, Muthiah Vaduganathan
Journal of Herbal Pharmacotherapy|March 8, 2006
The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS)Orly Vardeny, Mark B Bromberg
Cardiology Clinics|October 22, 2008
Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular riskOrly Vardeny, Scott D Solomon
Pharmacogenomics|November 5, 2016
Pharmacogenomics of heart failure: a systematic reviewFannie Mottet, Orly Vardeny, Simon de Denus
Heart Failure Reviews|May 26, 2026
Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art reviewHarriette G C Van Spall, Orly Vardeny
JACC. Heart Failure|October 13, 2014
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failureOrly Vardeny, Ryan Miller, Scott D Solomon
Heart Rhythm|July 2, 2020
Effects of hydroxychloroquine treatment on QT intervalMatthew Hooks, Bradley Bart, Orly Vardeny, et al.
Pageof 17